A retrospective study of renal safety following acute anti-VEGF exposure showed no significant change in mean eGFR and no episodes of acute kidney injury, following a single intravitreal anti-VEGF injection of ranibizumab, aflibercept or bevacizumab, in a cohort of 69 patients with DM and CKD [29]. This evidence concerns the gene VEGFA and chronic kidney disease.